- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
87
Companies which are potentially undervalued and in an acceptable financial position.
87 companies
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.95
7D
20.0%
1Y
-8.3%
Allogene Therapeutics
Market Cap: US$246.3m
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
ALLO
US$1.11
7D
-9.0%
1Y
-65.5%
Day One Biopharmaceuticals
Market Cap: US$747.8m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$9.14
7D
29.8%
1Y
-40.8%
BioMarin Pharmaceutical
Market Cap: US$10.1b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$52.80
7D
1.8%
1Y
-20.2%
Amgen
Market Cap: US$159.7b
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
AMGN
US$319.86
7D
9.6%
1Y
-0.6%
Gilead Sciences
Market Cap: US$152.8b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$122.58
7D
3.4%
1Y
33.7%
Agios Pharmaceuticals
Market Cap: US$2.3b
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
AGIO
US$40.51
7D
-3.5%
1Y
-21.5%
Annexon
Market Cap: US$338.5m
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
ANNX
US$3.01
7D
-5.6%
1Y
-59.7%
Forte Biosciences
Market Cap: US$194.6m
Operates as a clinical-stage biopharmaceutical company in the United States.
FBRX
US$10.30
7D
-28.4%
1Y
120.1%
Sangamo Therapeutics
Market Cap: US$169.4m
A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
SGMO
US$0.55
7D
-5.2%
1Y
-77.7%
Zai Lab
Market Cap: US$2.9b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$24.80
7D
-2.1%
1Y
-18.2%
Legend Biotech
Market Cap: US$5.9b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.01
7D
-0.4%
1Y
-22.7%
MiMedx Group
Market Cap: US$1.1b
Develops and distributes placental tissue allografts for various sectors of healthcare.
MDXG
US$7.96
7D
10.7%
1Y
6.1%
Exagen
Market Cap: US$237.0m
Designs, develops, and commercializes various testing products under the AVISE brand in the United States.
XGN
US$10.33
7D
-12.8%
1Y
309.4%
Scholar Rock Holding
Market Cap: US$2.7b
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
SRRK
US$27.97
7D
-4.5%
1Y
-5.6%